Fusion Antibodies plc
FAB.L · LSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | £2 | £1 | £3 | £5 |
| % Growth | 73% | -60.8% | -39.5% | – |
| Cost of Goods Sold | £2 | £1 | £3 | £3 |
| Gross Profit | £0 | -£0 | £0 | £2 |
| % Margin | 21.9% | -23.3% | 7% | 35.8% |
| R&D Expenses | £0 | £0 | £1 | £1 |
| G&A Expenses | £2 | £2 | £3 | £3 |
| SG&A Expenses | £2 | £2 | £2 | £2 |
| Sales & Mktg Exp. | -£0 | -£0 | -£1 | -£1 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £2 | £2 | £3 | £3 |
| Operating Income | -£2 | -£2 | -£3 | -£1 |
| % Margin | -90.5% | -201.4% | -97.7% | -27.8% |
| Other Income/Exp. Net | £0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | -£2 | -£2 | -£3 | -£1 |
| Tax Expense | £0 | -£0 | -£0 | -£0 |
| Net Income | -£2 | -£2 | -£3 | -£1 |
| % Margin | -87.2% | -196% | -89.5% | -25% |
| EPS | -0.018 | -0.04 | -0.1 | -0.046 |
| % Growth | 55.4% | 59.8% | -115.6% | – |
| EPS Diluted | -0.018 | -0.04 | -0.1 | -0.046 |
| Weighted Avg Shares Out | 96 | 56 | 26 | 26 |
| Weighted Avg Shares Out Dil | 96 | 56 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £1 |
| EBITDA | -£2 | -£2 | -£2 | -£1 |
| % Margin | -82.6% | -181.8% | -85.6% | -11.9% |